US20200207722A1 - Method for preparation of chlorinated s-propylthiobarbituric acid - Google Patents

Method for preparation of chlorinated s-propylthiobarbituric acid Download PDF

Info

Publication number
US20200207722A1
US20200207722A1 US16/621,222 US201816621222A US2020207722A1 US 20200207722 A1 US20200207722 A1 US 20200207722A1 US 201816621222 A US201816621222 A US 201816621222A US 2020207722 A1 US2020207722 A1 US 2020207722A1
Authority
US
United States
Prior art keywords
compound
formula
phos
sol
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US16/621,222
Other versions
US10689350B1 (en
Inventor
Michael Bersier
Paul Hanselmann
Candid Stoffel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza AG
Original Assignee
Lonza AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza AG filed Critical Lonza AG
Priority to US16/621,222 priority Critical patent/US10689350B1/en
Assigned to LONZA LTD reassignment LONZA LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HANSELMANN, PAUL, Bersier, Michael, STOFFEL, Candid
Application granted granted Critical
Publication of US10689350B1 publication Critical patent/US10689350B1/en
Publication of US20200207722A1 publication Critical patent/US20200207722A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals

Definitions

  • the invention discloses a method for preparation of 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine by conversion of 5-nitro-2-propylthiopyrimidine-4,6-diol with phosgene in the presence of DMF.
  • US 2013/0030176 A1 discloses of method for preparation of 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine and its use as intermediate for the preparation of ticagrelor.
  • Example 10 discloses a yield of 233.5 g of the 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine (MW 266 g/mol) with a purity of 99.45% is disclosed; with a MW of 229 g/mol for the substrate 5-nitro-2-propylthiopyrimidine-4,6-diol and a starting amount of 200 g the yield is 99.9%, which is admittedly very high.
  • the method has the advantage of comparably high yields without the problem of generation of H 3 PO 4 as waste.
  • Subject of the invention is a method for the preparation of compound of formula (2)
  • PHOS is selected from the group consisting of phosgene, diphosgene, triphosgene and mixtures thereof.
  • Compound of formula (1) is a known compound and can be produced by known methods.
  • PHOS is phosgene.
  • the molar amount of PHOS is from 2 to 5 times, more preferably from 2 to 4 times, even more preferably from 2 to 3 times, of the molar amount of compound of formula (1).
  • the amount of DMF is from 10 to 100 times, more preferably from 15 to 75 times, even more preferably from 15 to 50 times, especially from 15 to 40 times, more specially from 20 to 30 times, of the weight of PHOS.
  • the reaction temperature TEMP1 of REAC1 is from ⁇ 10 to 50° C., more preferably from ⁇ 5 to 40° C., even more preferably from ⁇ 5 to 30° C., especially from ⁇ 2.5 to 25° C.
  • reaction time TIME1 of REAC1 is from 5 h to 48 h, more preferably from 10 h to 24 h, even more preferably of from 12 h to 20 h.
  • REAC1 is in the beginning of TIME1 done at a lower temperature than at the end of TIME1;
  • REAC1 is done at first for 4.5 h to 41 h at ⁇ 10 to 9° C. and thereafter for 30 min to 7 h at 10 to 50° C.;
  • REAC1 is done at first for 9 h to 21 h at ⁇ 5 to 7° C. and thereafter for 1 h to 3 h at 12 to 40° C.;
  • REAC1 is done at first for 10.5 h to 19.5 h at ⁇ 5 to 50° C. and thereafter for 1.5 h to 2.5 h at 15 to 30° C.;
  • the DMF acts also as solvent in REAC1.
  • compound of formula (1) is dissolved in DMF to provide a solution SOL-1
  • PHOS is dissolved in DMF to provide a solution SOL-PHOS
  • SOL-1 and SOL-PHOS are mixed with each other to provide for REAC1; preferably, for the mixing of SOL-1 with SOL-PHOS, SOL-1 is added to SOL-PHOS.
  • the amount of DMF for preparation of SOL-1 is from 1 to 10 times, more preferably from 1.5 to 7.5 times, even more preferably from 2.5 to 7.5 times, of the weight of compound of formula (1);
  • the amount of DMF for preparation of SOL-PHOS is from 10 to 90 times, more preferably from 10 to 50 times, even more preferably from 15 to 40 times, especially from 15 to 30 times, of the weight of PHOS.
  • compound of formula (2) can be isolated and purified by conventional methods, which are known to those skilled in the art. These conventional methods include quenching the reaction mixture from REAC1 with water, with a solvent or with both water and a solvent, extraction, distillation, preferably fractional distillation, which can be done under reduced pressure, crystallization, chromatography, filtration, washing or any combination of these methods.
  • the solvent that is used for quenching the reaction mixture is preferably an organic solvent, more preferably toluene; preferably, the quenching is done with water and toluene, thereby two phases are generated; then the phases are separated and the organic phase is evaporated to provide compound of formula (2).
  • the amount of water is from 5 to 15 times, more preferably from 7.5 to 12.5 times, of the weight of compound of formula (1).
  • the amount of toluene is from 4 to 14 times, more preferably from 6.5 to 11 times, of the weight of compound of formula (1).
  • the addition of toluene and water is done at a temperature of from ⁇ 10 to 30° C., more preferably of from ⁇ 5 to 20° C., even more preferably of from ⁇ 5 to 15° C., especially of from ⁇ 5 to 10° C., more especially of from ⁇ 5 to 5° C., even more especially of from ⁇ 2.5 to 2.5° C.
  • HP-1 (SIMDIST), 15 m ⁇ 0.53 mm, 0.15 micrometer film-thickness, polydimethylsiloxane (or an equivalent column).
  • the GC results are given in area %.

Abstract

The invention discloses a method for preparation of 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine by conversion of 5-nitro-2-propylthiopyrimidine-4,6-diol with phosgene in the presence of DMF.

Description

  • The invention discloses a method for preparation of 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine by conversion of 5-nitro-2-propylthiopyrimidine-4,6-diol with phosgene in the presence of DMF.
  • BACKGROUND OF THE INVENTION
  • US 2013/0030176 A1 discloses of method for preparation of 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine and its use as intermediate for the preparation of ticagrelor.
  • Example 10 discloses a yield of 233.5 g of the 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine (MW 266 g/mol) with a purity of 99.45% is disclosed; with a MW of 229 g/mol for the substrate 5-nitro-2-propylthiopyrimidine-4,6-diol and a starting amount of 200 g the yield is 99.9%, which is admittedly very high.
  • Nevertheless the method uses phosphorous oxychloride (MW 153 g/mol) as Cl source for the exchange of the OH residues against Cl. The given 425.6 g of phosphorous oxychloride are converted by the reaction ultimately to 271 g phosphoric acid H3PO4 (MW 100). So 1.16 times, of the weight of the product, of phosphoric acid needs to be disposed of. This waste is a serious environmental challenge as well as a cost factor.
  • There was a need for a process that does not pose the mentioned waste problem in form of H3PO4.
  • An extensive screening of phosgene as alternative Cl source without catalyst, with various catalysts and with various solvents was not successful but showing yields of not more than 32%, instead showing significant amounts of undesired by products, as documented herein under Comparative Examples 1 to 60. Only one combination, the combination of phosgene with DMF, surprisingly showed satisfying yields.
  • The method has the advantage of comparably high yields without the problem of generation of H3PO4 as waste.
  • The following abbreviations are used, if not otherwise stated:
  • compound of formula (1) 5-nitro-2-propylthiopyrimidine-4,6-diol, also called 5-nitro-2-propylsulfanyl-pyrimidine-4,6-diol
  • compound of formula (2) 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
  • DMF dimethyl formamide
  • eq equivalent
  • RT room temperature
  • MW molecular weight
  • SUMMARY OF THE INVENTION
  • Subject of the invention is a method for the preparation of compound of formula (2)
  • Figure US20200207722A1-20200702-C00001
  • by a reaction REAC1 of compound of formula (1)
  • Figure US20200207722A1-20200702-C00002
  • with a compound PHOS in the presence of DMF;
  • PHOS is selected from the group consisting of phosgene, diphosgene, triphosgene and mixtures thereof.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Compound of formula (1) is a known compound and can be produced by known methods.
  • Preferably, PHOS is phosgene.
  • Preferably, the molar amount of PHOS is from 2 to 5 times, more preferably from 2 to 4 times, even more preferably from 2 to 3 times, of the molar amount of compound of formula (1).
  • Preferably, the amount of DMF is from 10 to 100 times, more preferably from 15 to 75 times, even more preferably from 15 to 50 times, especially from 15 to 40 times, more specially from 20 to 30 times, of the weight of PHOS.
  • Preferably, the reaction temperature TEMP1 of REAC1 is from −10 to 50° C., more preferably from −5 to 40° C., even more preferably from −5 to 30° C., especially from −2.5 to 25° C.
  • Preferably, the reaction time TIME1 of REAC1 is from 5 h to 48 h, more preferably from 10 h to 24 h, even more preferably of from 12 h to 20 h.
  • In one embodiment, REAC1 is in the beginning of TIME1 done at a lower temperature than at the end of TIME1;
  • preferably, REAC1 is done at first for 4.5 h to 41 h at −10 to 9° C. and thereafter for 30 min to 7 h at 10 to 50° C.;
  • more preferably, REAC1 is done at first for 9 h to 21 h at −5 to 7° C. and thereafter for 1 h to 3 h at 12 to 40° C.;
  • even more preferably, REAC1 is done at first for 10.5 h to 19.5 h at −5 to 50° C. and thereafter for 1.5 h to 2.5 h at 15 to 30° C.;
  • Preferably, the DMF acts also as solvent in REAC1.
  • More preferably, compound of formula (1) is dissolved in DMF to provide a solution SOL-1, and PHOS is dissolved in DMF to provide a solution SOL-PHOS; and SOL-1 and SOL-PHOS are mixed with each other to provide for REAC1; preferably, for the mixing of SOL-1 with SOL-PHOS, SOL-1 is added to SOL-PHOS.
  • Therefore in one embodiment, the amount of DMF for preparation of SOL-1 is from 1 to 10 times, more preferably from 1.5 to 7.5 times, even more preferably from 2.5 to 7.5 times, of the weight of compound of formula (1); and
  • the amount of DMF for preparation of SOL-PHOS is from 10 to 90 times, more preferably from 10 to 50 times, even more preferably from 15 to 40 times, especially from 15 to 30 times, of the weight of PHOS.
  • After REAC1, compound of formula (2) can be isolated and purified by conventional methods, which are known to those skilled in the art. These conventional methods include quenching the reaction mixture from REAC1 with water, with a solvent or with both water and a solvent, extraction, distillation, preferably fractional distillation, which can be done under reduced pressure, crystallization, chromatography, filtration, washing or any combination of these methods.
  • Preferably, the solvent that is used for quenching the reaction mixture is preferably an organic solvent, more preferably toluene; preferably, the quenching is done with water and toluene, thereby two phases are generated; then the phases are separated and the organic phase is evaporated to provide compound of formula (2).
  • Preferably, after REAC1 toluene and water is added to the reaction mixture.
  • Preferably, the amount of water is from 5 to 15 times, more preferably from 7.5 to 12.5 times, of the weight of compound of formula (1).
  • Preferably, the amount of toluene is from 4 to 14 times, more preferably from 6.5 to 11 times, of the weight of compound of formula (1).
  • Preferably, the addition of toluene and water is done at a temperature of from −10 to 30° C., more preferably of from −5 to 20° C., even more preferably of from −5 to 15° C., especially of from −5 to 10° C., more especially of from −5 to 5° C., even more especially of from −2.5 to 2.5° C.
  • Examples
  • Compound of formula (3):
  • Figure US20200207722A1-20200702-C00003
  • Compound of formula (4):
  • Figure US20200207722A1-20200702-C00004
  • Compound of formula (5):
  • Figure US20200207722A1-20200702-C00005
  • GC Method
  • Instrument:
  • Hewlett Packard gas chromatograph 6890 with a split injector and a flame ionisation detector or an instrument with corresponding performance and quality.
  • Column:
  • HP-1 (SIMDIST), 15 m×0.53 mm, 0.15 micrometer film-thickness, polydimethylsiloxane (or an equivalent column).
  • Instrument. Settings:
  • Oven:
  • INITIAL TEMP 50° C.
    HOLD 2 min
    RAMP 1 20° C./min
    NEXT TEMP 320° C.
    HOLD 10 min
  • Injector:
  • Injection volume 1 microliter
    Check the auto-injector parameters
  • Inlets:
  • INJ. MODE Split
    INJ TEMP 250° C.
    SPLIT FLOW 200 ml/min
    SPLIT RATIO 25:1
    MODE constant flow 8.0 ml/min
  • Detectors:
  • DET TEMP 300° C.
    Check the FID gas flow rates
  • The GC results are given in area %.
  • Comparative Examples 1 to 42—with Base
  • 5.0 g (21.62 mmol, 1 eq) of compound of formula (1) were dissolved in 25 mL of solvent SOLV and base was added. 100 mL of SOLV were mixed with 4.7 g of phosgene (47.56 mmol. 2.2 eq) at 0° C. The solution of compound of formula (1) and base was added at 0° C. to the mixture of SOLV with phosgene. After stirring for 5 h at 0° C. and then for 2 h at RT, a sample from the reaction mixture was taken and analysed with GC. Result are shown in Table 1 with the following abbreviations:
  • CE Comparative Example
  • DPA-2.2 Diisopropylamine, 2.2 eq
  • DPA-2.5 Diisopropylamine, 2.5 eq
  • EMP-2.2 5-Ethyl-2-methylpyridine, 2.2 eq
  • NMM-2.2 N-Methylmorpholine, 2.2 eq
  • TEA-2.2 Triethylamine (2.2 eq.)
  • (2) compound of formula (2)
  • (3) compound of formula (2)
  • (4) compound of formula (4)
  • TABLE 1
    GC Results
    CE Base SOLV (2) (3) (4)
    1 DPA-2.2 Dichloromethane 20% 15% 10%
    2 DPA-2.2 Toluene 25% 12%  8%
    3 DPA-2.2 Acetonitrile 30% 17% 12%
    4 DPA-2.2 Chlorobenzene 10% 18%  9%
    5 DPA-2.2 Sulfolane 32% 12% 14%
    6 DPA-2.2 Dimethyl carbonate 12% 19%  5%
    7 DPA-2.5 Dichloromethane 20% 15% 10%
    8 DPA-2.5 Toluene 25% 12%  8%
    9 DPA-2.5 Acetonitrile 30% 17% 12%
    10 DPA-2.5 Chlorobenzene 10% 18%  9%
    11 DPA-2.5 Sulfolane 32% 12% 14%
    12 DPA-2.5 Dimethyl carbonate 12% 19%  5%
    13 3-Picoline Dichloromethane 21% 18% 11%
    (2.2 eq.)
    14 3-Picoline Toluene 28% 13%  8%
    (2.2 eq.)
    15 3-Picoline Acetonitrile 31% 12%  7%
    (2.2 eq.)
    16 3-Picoline Chlorobenzene 17% 22% 15%
    (2.2 eq.)
    17 3-Picoline Sulfolane 22% 18% 10%
    (2.2 eq.)
    18 3-Picoline Dimethyl carbonate 28% 11% 15%
    (2.2 eq.)
    19 TEA-2.2 Dichloromethane 20% 14%  8%
    20 TEA-2.2 Toluene 25% 12%  8%
    21 TEA-2.2 Acetonitrile 30% 17% 12%
    22 TEA-2.2 Chlorobenzene 10% 18%  9%
    23 TEA-2.2 Sulfolane 32% 12% 14%
    24 TEA-2.2 Dimethyl carbonate 12% 19%  5%
    25 Pyridine Dichloromethane 20% 15% 10%
    (2.2 eq.)
    26 Pyridine Toluene 25% 12%  8%
    (2.2 eq.)
    27 Pyridine Acetonitrile 30% 17% 12%
    (2.2 eq.)
    28 Pyridine Chlorobenzene 12% 19%  5%
    (2.2 eq.)
    29 Pyridine Sulfolane 20% 15% 10%
    (2.2 eq.)
    30 Pyridine Dimethyl carbonate 25% 12%  8%
    (2.2 eq.)
    31 EMP-2.2 Dichloromethane 30% 17% 12%
    32 EMP-2.2 Toluene 10% 18%  9%
    33 EMP-2.2 Acetonitrile 32% 12% 14%
    34 EMP-2.2 Chlorobenzene 12% 19%  5%
    35 EMP-2.2 Sulfolane 21% 18% 11%
    36 EMP-2.2 Dimethyl carbonate 28% 13%  8%
    37 NMM-2.2 Dichloromethane 16% 15%  8%
    38 NMM-2.2 Toluene 20% 15% 15%
    39 NMM-2.2 Acetonitrile 18% 15%  5%
    40 NMM-2.2 Chlorobenzene 20% 18% 10%
    41 NMM-2.2 Sulfolane 22% 18% 10%
    42 NMM-2.2 Dimethyl carbonate 28% 15%  8%
  • Comparative Examples 43 to 60—without Base
  • 5.0 g (21.62 mmol, 1 eq) of compound of formula (1) were dissolved in 125 mL of solvent SOLV and Catalyst was added. 4.7 g of phosgene (47.56 mmol, 2.2 eq) were added at 0° C. After 5 h at 0° C., then 2 h at RT and then 2 h at 40° C., a sample from the reaction mixture was taken and analysed with GC.
  • Result are shown in Table 2 with the following abbreviations:
  • (2) compound of formula (2)
  • CE Comparative Example
  • TPP-0.1 Triphenylphosphine, 0.1 eq
  • TPP-0.3 Triphenylphosphine, 0.3 eq
  • TABLE 2
    CE Catalyst SOLV Remarks
    43 TPP-0.1 Dichloromethane less than 0.5% of (2)
    44 TPP-0.1 Toluene less than 0.5% of (2)
    45 TPP-0.1 Acetonitrile less than 0.5% of (2)
    46 TPP-0.1 Chlorobenzene less than 0.5% of (2)
    47 TPP-0.1 Sulfolane less than 0.5% of (2)
    48 TPP-0.1 Dimethyl carbonate less than 0.5% of (2)
    49 TPP-0.3 Dichloromethane less than 0.5% of (2)
    50 TPP-0.3 Toluene less than 0.5% of (2)
    51 TPP-0.3 Acetonitrile less than 0.5% of (2)
    52 TPP-0.3 Chlorobenzene less than 0.5% of (2)
    53 TPP-0.3 Sulfolane less than 0.5% of (2)
    54 TPP-0.3 Dimethyl carbonate less than 0.5% of (2)
    55 no catalyst Dichloromethane less than 0.5% of (2)
    56 no catalyst Toluene less than 0.5% of (2)
    57 no catalyst Acetonitrile less than 0.5% of (2)
    58 no catalyst Chlorobenzene less than 0.5% of (2)
    59 no catalyst Sulfolane less than 0.5% of (2)
    60 no catalyst Dimethyl carbonate less than 0.5% of 2
  • Example 1—with DMF
  • 5.0 g (21.62 mmol, 1 eq) compound of formula (1) were dissolved in 25 mL of DMF. 100 mL of DMF were mixed with 4.7 g of phosgene (47.56 mmol, 2.2 eq) at 0° C. The solution of compound of formula (1) was added to the mixture of DMF with phosgene at 0° C. After 14 h stirring at 0° C. and then 2 h at RT, 50 mL of water and 50 mL of toluene were added at 0° C. The mixture was stirred 15 min and the phases were separated. The organic phase was evaporated under vacuum. 5 g of compound of formula (2) were isolated (83% yield, 98.2% purity, GC analysis showed 1.1% of compound of formula (3), 0.32% of compound of formula (4) and 0.35% of compound of formula (5)).
  • Example 2—with DMF
  • 50 g (216.2 mmol, 1 eq) of compound of formula (1) were dissolved in 250 mL of DMF. 1000 mL of DMF were mixed with 47 g of phosgene (475.6 mmol, 2.2 eq) at 0° C. The solution of compound of formula (1) was added to the mixture of DMF with phosgene at 0° C. After 14 h stirring at 0° C. and then 2 h at RT, 500 mL of water and 500 mL of toluene were added at 0° C. The mixture was stirred 30 min and the phases were separated. The organic phase was evaporated under vacuum. 54 g of compound of formula (2) were isolated (93% yield, 98.4% purity, GC analysis showed 1.1% of compound of formula (3), 0.26% of compound of formula (4) and 0.24% of compound of formula (5)).

Claims (10)

1. Method for the preparation of compound of formula (2)
Figure US20200207722A1-20200702-C00006
by a reaction REAC1 of compound of formula (1)
Figure US20200207722A1-20200702-C00007
with a compound PHOS in the presence of DMF;
PHOS is selected from the group consisting of phosgene, diphosgene, triphosgene and mixtures thereof.
2. Method according to claim 1, wherein
PHOS is phosgene.
3. Method according to claim 1, wherein
the molar amount of PHOS is from 2 to 5 times of the molar amount of compound of formula (1).
4. Method according to claim 1, wherein
the amount of DMF is from 10 to 100 times of the weight of PHOS.
5. Method according to claim 1, wherein the reaction temperature TEMP1 of REAC1 is from −10 to 50° C.
6. Method according to claim 1, wherein the reaction time TIME1 of REAC1 is from 5 h to 48 h.
7. Method according to claim 1, wherein compound of formula (1) is dissolved in DMF to provide a solution SOL-1, and PHOS is dissolved in DMF to provide a solution SOL-PHOS; and SOL-1 and SOL-PHOS are mixed with each other to provide for REAC1.
8. Method according to claim 7, wherein for the mixing of SOL-1 with SOL-PHOS, SOL-1 is added to SOL-PHOS.
9. Method according to claim 1, wherein after REAC1 toluene and water is added to the reaction mixture.
10. Method according to claim 1, wherein the addition of toluene and water is done at a temperature of from −10 to 30° C.
US16/621,222 2017-07-18 2018-07-16 Method for preparation of chlorinated s-propylthiobarbituric acid Active US10689350B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/621,222 US10689350B1 (en) 2017-07-18 2018-07-16 Method for preparation of chlorinated s-propylthiobarbituric acid

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762533838P 2017-07-18 2017-07-18
EP17181961.8 2017-07-18
EP17181961 2017-07-18
EP17181961 2017-07-18
US16/621,222 US10689350B1 (en) 2017-07-18 2018-07-16 Method for preparation of chlorinated s-propylthiobarbituric acid
PCT/EP2018/069193 WO2019016111A1 (en) 2017-07-18 2018-07-16 Method for preparation of chlorinated s-propylthiobarbituric acid

Publications (2)

Publication Number Publication Date
US10689350B1 US10689350B1 (en) 2020-06-23
US20200207722A1 true US20200207722A1 (en) 2020-07-02

Family

ID=62981195

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/621,222 Active US10689350B1 (en) 2017-07-18 2018-07-16 Method for preparation of chlorinated s-propylthiobarbituric acid

Country Status (5)

Country Link
US (1) US10689350B1 (en)
EP (1) EP3619198B1 (en)
JP (1) JP6722365B1 (en)
CN (1) CN110831928A (en)
WO (1) WO2019016111A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702772D0 (en) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US20020042514A1 (en) * 2000-06-26 2002-04-11 Doyle Timothy John Synthesis of chlorinated pyrimidines
CA2451128A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
EP2459564B1 (en) * 2009-07-27 2016-09-07 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
KR101141104B1 (en) * 2010-05-11 2012-05-02 한국과학기술원 Metal-Porphyrinic Carbon Nanotube Used for Electrodes of Fuel Cell
MX2013007115A (en) 2010-12-20 2014-02-10 Actavis Group Ptc Ehf Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof.

Also Published As

Publication number Publication date
JP6722365B1 (en) 2020-07-15
CN110831928A (en) 2020-02-21
US10689350B1 (en) 2020-06-23
WO2019016111A1 (en) 2019-01-24
EP3619198A1 (en) 2020-03-11
EP3619198B1 (en) 2020-06-17
JP2020526480A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
EP3331857B1 (en) Process for fluorinating compounds
EP3487837B1 (en) Process for the preparation of spiroheterocyclic pyrrolidine dione herbicides by means of the intermediate compound 2-(4-chloro-2,6-dimethyl-phenyl)acetic acid
AU2018250429B2 (en) Method for preparing azoxystrobin
JPS596852B2 (en) Method for producing 2,2,6,6-tetramethyl-4-oxopiperidine
JP2019528324A (en) Synthesis of 1-hydroxyethylformamide and N-vinylformamide
US10689350B1 (en) Method for preparation of chlorinated s-propylthiobarbituric acid
US4981996A (en) Method for the production of O-substituted hydroxylamines
CN111943901B (en) Method for directly synthesizing oxazolidine-2, 4-diketone heterocyclic compound from alkynylamide
WO2022038166A1 (en) Amide coupling process
Van Gool et al. An easy and versatile synthesis of ureas from 2-benzylaminopyrimidine
US6441171B1 (en) Method for the production of 4,6-dichloropyrimidine with the aid of phosgene
JP5067752B2 (en) Method for producing phosphate ester
CN106146485A (en) A kind of method preparing safe ground azoles amine and the safe ground azoles amine crystalline solid obtained thereof
EP3660005A1 (en) Method for preparing azoxystrobin
EP0103126B1 (en) Process for preparing 4-amino-5-dialkoxymethylpyrimidine derivatives
GB2115809A (en) Process for preparing 4-amino-5-dialkoxy-methylpyrimidine derivatives
Kumar et al. Synthesis and characterization of potential impurity of muscle relaxant drug carisoprodol
JPH0565255A (en) Enamino esters and its production
JP4526385B2 (en) Process for the preparation of 4,6-dichloro-5-fluoropyrimidine
JPS63162662A (en) Production of isophorone diisocyanate
EP1000929B1 (en) Process for preparing o-nitrobenzonitriles
US6822095B1 (en) Method for producing 4,6-dichloropyrimidine
CN104447414A (en) Bis-substituted allyl carbamate compound and synthesis method thereof
JP2019019091A (en) Method for producing fluoroalkyl nitrile
CN101263128B (en) Method for sulfonation of 1,2-benzisoxazole-3-acetic acid

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: LONZA LTD, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERSIER, MICHAEL;HANSELMANN, PAUL;STOFFEL, CANDID;SIGNING DATES FROM 20200106 TO 20200108;REEL/FRAME:051466/0537

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY